Overview of the European Medicines Agency's Experience With Biowaivers in Centralized Applications

Overview of the European Medicines Agency's Experience With Biowaivers in Centralized Applications

The waiver of the in vivo demonstration of bioequivalence (biowaiver) is an established tool in drug development and regulatory assessment. This study reviews the use of different biowaiver approaches in centralized applications for marketing authorization to the European Medicines Agency for generi...

Full description

Bibliographic Details
Main Authors:	Ines Lenić, Kevin Blake, Alfredo Garcia‐Arieta, Henrike Potthast, Jan Welink
Format:	Article
Language:	English
Published:	Wiley 2019-09-01
Series:	Clinical and Translational Science
Online Access:	https://doi.org/10.1111/cts.12642

Similar Items

Biowaiver as a Bioequivalence Study Option
by: E. A. Volkova, et al.
Published: (2024-02-01)

Comparator product issues for biowaiver implementation: the case of Fluconazole
by: Raul Edison Luna Lazo, et al.
Published: (2022-07-01)

Biopharmaceutics classification system: importance and inclusion in biowaiver guidance
by: Lorena Barbosa Arrunátegui, et al.
Published: (2015-03-01)

The Requirements for Additional Strength Biowaivers for Immediate Release Solid Oral Dosage Forms in International Pharmaceutical Regulators Programme Participating Regulators and Organisations: Differences and Commonalities
by: Christopher Crane, et al.
Published: (2020-08-01)

Using mechanistic models to support development of complex generic drug products: European Medicines Agency perspective
by: Efthymios Manolis, et al.
Published: (2023-05-01)

Requirements for Additional Strength Biowaivers for Modified Release Solid Oral Dosage Forms in International Pharmaceutical Regulators Programme Participating Regulators and Organisations: Differences and Commonalities
by: Matthias Shona Roost, et al.
Published: (2021-10-01)

Gliclazide: Biopharmaceutics Characteristics to Discuss the Biowaiver of Immediate and Extended Release Tablets
by: Bruna de Carvalho Mapa, et al.
Published: (2020-10-01)

Development and validation of a UV spectrophotometric method for biowaiver studies in pyrazinamide tablets
by: Vanessa Saldaña-Bobadilla, et al.
Published: (2024-05-01)

DISSOLUTION PROFILE STUDIES OF BCS CLASS II DRUG VALSARTAN BY BIOWAIVER PROCEDURE
by: E. R. Brigas, et al.
Published: (2019-01-01)

Biowaiver for Immediate and Modified Release Dosage forms Scientific summary of the CSPS workshop
by: Raimar Loebenberg
Published: (2020-08-01)

Effects of experimental conditions on solubility measurements for BCS classification in order to improve the biowaiver guidelines
by: Patrícia Fernanda Monteiro, et al.
Published: (2021-11-01)

European Space Agency: an Overview of the Legal Frame
by: Inessa Kostenko
Published: (2019-03-01)

RETRACTED: International experience in drug names assessment: European Medicines Agency
by: A. N. Mironov, et al.
Published: (2018-12-01)

The European Medicines Agency and Family Doctors
by: Mary McCarthy
Published: (2018-08-01)

A Survey of the Regulatory Requirements for BCS-Based Biowaivers for Solid Oral Dosage Forms by Participating Regulators and Organisations of the International Generic Drug Regulators Programme
by: Joy Elizabeth van Oudtshoorn, et al.
Published: (2018-03-01)

Differentiating Agency Independence: Perceptions from Inside the European Medicines Agency
by: Levan Makhashvili, et al.
Published: (2013-01-01)

Differentiating Agency Independence: Perceptions from Inside the European Medicines Agency
by: Levan Makhashvili, et al.
Published: (2013-02-01)

Utility of in vitro release testing (IVRT) to assess ‘sameness’ of 1% clotrimazole creams for use as a biowaiver
by: Hannah Wellington, et al.
Published: (2023-11-01)

<b>Biowaiver study of oral tabletted ethylcellulose microcapsules of a BCS class I drug</b>
by: Ghulam Murtaza, et al.
Published: (2009-08-01)

Physician Involvement in the Activities of the European Medicines Agency
by: Ivana Silva
Published: (2017-11-01)

ICH Guideline for Biopharmaceutics Classification System-Based Biowaiver (M9): Toward Harmonization in Latin American Countries
by: Claudia Miranda, et al.
Published: (2021-03-01)

Comparison of in vitro, in vivo, and in silico bioavailability results of different prednisone tablet formulations to assess the feasibility of possible biowaiver
by: Leonardo Henrique Toehwé, et al.
Published: (2021-11-01)

EUROPEAN MEDICINES AGENCY APPROVED APIXABAN USE IN CARDIOVERSION
Published: (2015-09-01)

EUROPEAN MEDICINES AGENCY APPROVED APIXABAN USE IN CARDIOVERSION
Published: (2015-09-01)

EUROPEAN MEDICINES AGENCY APPROVED APIXABAN USE IN CARDIOVERSION
Published: (2015-09-01)

Latest clinical recommendations on valproate use for migraine prophylaxis in women of childbearing age: overview from European Medicines Agency and European Headache Federation
by: Efstratia Vatzaki, et al.
Published: (2018-08-01)

Disinvestment in healthcare: an overview of HTA agencies and organizations activities at European level
by: G. E. Calabrò, et al.
Published: (2018-03-01)

The Iterative Development of Medicines Through the European Medicine Agency's Adaptive Pathway Approach
by: Giuseppe Nicotera, et al.
Published: (2019-06-01)

Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies
by: Lourens T. Bloem, et al.
Published: (2021-07-01)

Regulatory requirements of the European Medicines Agency for evaluation of bioequivalence of modified-release medicinal products
by: D. P. Romodanovsky, et al.
Published: (2019-03-01)

Stratified medicine in practice: review of predictive biomarkers in European Medicines Agency (EMA) indications
by: Malottki Kinga, et al.
Published: (2011-12-01)

Biomarker and Companion Diagnostics—A Review of Medicinal Products Approved by the European Medicines Agency
by: Laura Patricia Orellana García, et al.
Published: (2021-11-01)

Improving Risk Assessment in the European Food Safety Authority: Lessons From the European Medicines Agency
by: Sevasti Chatzopoulou, et al.
Published: (2020-04-01)

Involvement of the European Medicines Agency in multi-stakeholder regulatory science research projects: experiences of staff members and project coordinators
by: Robbe Saesen, et al.
Published: (2023-05-01)

Extension of the European Medicines Agency (EMA) approval of trifluridine/tipiracil for gastric cancer
by: Maria Alsina, et al.
Published: (2019-09-01)

European Medicines Agency (EMA) announces termination of Avandia (rosiglitazone usage in Europe)
by: Inna Igorevna Klefortova
Published: (2010-09-01)

Regulatory Science to 2025: An Analysis of Stakeholder Responses to the European Medicines Agency's Strategy
by: Philip A. Hines, et al.
Published: (2020-09-01)

Access to regulatory data from the European Medicines Agency: the times they are a-changing
by: Wieseler Beate, et al.
Published: (2012-10-01)

The European Medicines Agency's scientific opinion on oral fexinidazole for human African trypanosomiasis.
by: Eric Pelfrene, et al.
Published: (2019-06-01)

The new European Medicines Agency guideline on antidepressants: a guide for researchers and drug developers
by: Florence Butlen-Ducuing, et al.
Published: (2024-01-01)